Clinical Trials Directory

A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma

Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of infection. Therefore, we propose a clinical study with allogeneic HSCT using a unique non-myeloablative preparative regimen, TLI/ATG, to treat advanced MF/SS.

Stanford is now accepting new patients for this trial.



  • drug : cyclosporine
  • drug : anti-thymocyte globulin

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

3.1 Inclusion Criteria 3.1.1 Stage IIB-IV mycosis fungoides or Sezary syndrome, who have failed at least 1 standard systemic therapy or are not candidates for standard therapy. 3.1.2 Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center. 3.1.4 Age > 18 years and <= 75 years. 3.1.5 Karnofsky Performance Status >= 70%. 3.1.6 Corrected DLCO >= 40% 3.1.7 Left ventricle ejection fraction (LVEF) > 30%. 3.1.8 ALT and AST must be <= 3X normal. Total bilirubin <= 3 mg/dL unless hemolysis or Gilbert's disease. 3.1.9 Estimated creatinine clearance >= 50 ml/min. 3.1.10 Have a related or unrelated HLA-identical donor or one antigen/allele mismatched in HLA-A, B, C or DRB1. 3.1.11 Signed informed consent. 3.3 Donor Inclusion Criteria 3.3.1 Age >=17. 3.3.2 HIV seronegative. 3.3.3 Signed informed consent. 3.3.4 No contraindication to the administration of G-CSF. 3.3.5 Willing to have a central venous catheter placed for apheresis if peripheral veins are inadequate. 3.5 Enrollment Enrollment occurs when all eligibility criteria are met.

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Physician Referrals

Footer Links: